Clearmind Medicine (CMND) News Today $1.02 +0.02 (+1.49%) As of 10:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMND Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant EnrolledJuly 15 at 8:43 AM | globenewswire.comClearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant EnrolledJuly 15 at 8:43 AM | globenewswire.comClearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center - Seeking AlphaJuly 5, 2025 | seekingalpha.comClearmind Gains IRB Approval At TASMC For Alcohol Use Disorder Drug Trial - NasdaqJuly 5, 2025 | nasdaq.comClearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical CenterJuly 3, 2025 | globenewswire.comClearmind Medicine Inc.: Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for ... - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deClearmind Medicine Inc. Achieves Milestone in Clinical Trial for Alcohol Use Disorder with Dosing of First Participant in Phase I/IIa Trial of CMND-100 - NasdaqJuly 2, 2025 | nasdaq.comClearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use DisorderJune 30, 2025 | globenewswire.comClearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market - MorningstarJune 29, 2025 | morningstar.comMClearmind Medicine Inc. Expands Clinical Trial for Alcohol Use Disorder with Addition of Hadassah-University Medical Center - NasdaqJune 29, 2025 | nasdaq.comClearmind Medicine expands global clinical trial targeting AUD marketJune 28, 2025 | yahoo.comClearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder MarketJune 27, 2025 | globenewswire.comClearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics - MorningstarJune 25, 2025 | morningstar.comMClearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics - MorningstarJune 25, 2025 | morningstar.comMClearmind Medicine Inc. Engages Consulting Firm to Advance Psychedelic-Based Treatments and Regulatory Advocacy - NasdaqJune 25, 2025 | nasdaq.comClearmind Medicine Inc. Engages Consulting Firm to Advance Psychedelic-Based Treatments and Regulatory Advocacy - NasdaqJune 25, 2025 | nasdaq.comClearmind Medicine Inc. Expands Phase I/IIa Clinical Trial for CMND-100 with Tel Aviv Sourasky Medical Center Collaboration - NasdaqJune 25, 2025 | nasdaq.comClearmind Medicine Inc. Expands Phase I/IIa Clinical Trial for CMND-100 with Tel Aviv Sourasky Medical Center Collaboration - NasdaqJune 25, 2025 | nasdaq.comClearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism TreatmentJune 25, 2025 | globenewswire.comClearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic TherapeuticsJune 24, 2025 | globenewswire.comClearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use DisorderJune 23, 2025 | globenewswire.comClearmind Medicine Partners with Leading Government Affairs Firm to Advance Psychedelic TherapeuticsJune 14, 2025 | nasdaq.comClearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic TherapeuticsJune 12, 2025 | globenewswire.comClearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder TreatmentJune 5, 2025 | globenewswire.comClearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic ExpertsMay 20, 2025 | globenewswire.comClearmind Medicine files patent for eating disorder treatmentApril 26, 2025 | investing.comClearmind Medicine files patent for eating disorder treatmentApril 26, 2025 | investing.comClearmind Medicine Inc.: Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating DisordersApril 25, 2025 | finanznachrichten.deSciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating DisordersApril 25, 2025 | globenewswire.comClearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating DisordersApril 25, 2025 | globenewswire.comPsychedelic: Clearmind completes clinical site initiations for AUD trialApril 25, 2025 | markets.businessinsider.comClearmind Medicine completes initiation of AUD Phase I/IIa trialApril 24, 2025 | markets.businessinsider.comClearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical SitesApril 23, 2025 | globenewswire.comClearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic ExpertsApril 21, 2025 | globenewswire.comClearmind Medicine begins phase I/IIa trial for AUD treatmentApril 18, 2025 | uk.investing.comClearmind Medicine Inc.: Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge BehaviorApril 17, 2025 | finanznachrichten.deClearmind Medicine launches first U.S. clinical site for AUD trialApril 17, 2025 | markets.businessinsider.comClearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge BehaviorApril 17, 2025 | globenewswire.comClearmind Medicine Inc.: Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat AlcoholismApril 16, 2025 | finanznachrichten.deClearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat AlcoholismApril 16, 2025 | globenewswire.comClearmind Medicine announces U.S. clinical site initiation for CMND-100 trialApril 10, 2025 | markets.businessinsider.comPsychedelic: Clearmind initiates U.S. clinical site for CMND-100 trialApril 10, 2025 | markets.businessinsider.comClearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use DisorderApril 10, 2025 | globenewswire.comClearmind announces patent application for psychedelic-based compoundsApril 8, 2025 | markets.businessinsider.comClearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health DisordersApril 8, 2025 | globenewswire.comClearmind launches data system for alcohol addiction trialApril 3, 2025 | uk.investing.comClearmind Medicine launches EDC system to support Phase I/II trialApril 2, 2025 | markets.businessinsider.comClearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based TreatmentApril 1, 2025 | globenewswire.comPsychedelic: Exclusive talk with biotech company Clearmind MedicineMarch 22, 2025 | finance.yahoo.comClearmind Medicine says CMND-100 arrives in the U.S.March 21, 2025 | markets.businessinsider.com Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address CMND Media Mentions By Week CMND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMND News Sentiment▼0.740.96▲Average Medical News Sentiment CMND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMND Articles This Week▼21▲CMND Articles Average Week Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LPCN News Today QTTB News Today CARM News Today CASI News Today GELS News Today HOTH News Today LEXX News Today BIVI News Today SONN News Today ALLR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMND) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredNew crypto laws coming. Will you win or lose?Washington’s first-ever “Crypto Week” could trigger a major Bitcoin surge — but one trader says don’t just buy...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
